Lawmakers, Generic Industry Push for More Legislative Support

Generic drugs have saved the U.S. more than $1 trillion over the past decade, a figure that well exceeds predictions from when the Hatch-Waxman Act was enacted in 1984, according to a new study. But despite this astronomical number, generic-drug makers and key lawmakers say more could be done to fuel competition. The Generic Pharmaceutical Association (GPhA) will continue to push for a cost-saving measure that would allow generic companies access to hard-to-obtain drugs with risk evaluation and mitigation strategies, GPhA CEO Ralph Neas said at a meeting to present GPhA’s new report.
Washington Drug Letter